J.P. Morgan analysts expect the global market for GLP-1 drugs to exceed $100 billion over time.
“From the perspective of the pharma companies, we see the market for the GLP-1 category exceeding $100 billion over time globally.”
Person
1 episodes · 5 quoted claims
J.P. Morgan analysts expect the global market for GLP-1 drugs to exceed $100 billion over time.
“From the perspective of the pharma companies, we see the market for the GLP-1 category exceeding $100 billion over time globally.”
Novo Nordisk released results of its SELECT cardiovascular outcomes study in August 2023, which coincided with a split in healthcare stock performance.
“especially around August when we had the select study from NOAA Nordisk looking at the cardiovascular outcomes”
Medical device companies underperformed in 2023 amid fears about the impact of GLP-1 drugs.
“While companies on the medical device side of things, they really underperformed over these GLP-1 fears.”
The SELECT study showed Wegovy reduced the risk of heart attacks, strokes and cardiovascular death by about 20%.
“not only helped people to lose weight, but also reduced their risk of suffering from heart attacks, strokes, cardiovascular deaths by 20%”
J.P. Morgan's Chris Schott has estimated the U.S. obesity drug opportunity at approaching $50 billion by 2030.
“you previously said that you estimate obesity opportunity in the U.S. approaching 50 billion by 2030”